These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38038346)

  • 1. Comparative Performance of 2018 LI-RADS versus Modified LIRADS (mLI-RADS): An Individual Participant Data Meta-Analysis.
    Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Clarke C; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kierans AS; Kim SY; Kwon H; Podgórska J; Rosiak G; Bashir MR
    J Magn Reson Imaging; 2024 Sep; 60(3):1082-1091. PubMed ID: 38038346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
    Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
    Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
    Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Tang A; Alhasan AS; Allen BC; Reiner CS; Clarke C; Cerny M; Wang J; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kang Z; Kierans AS; Kim SY; Kwon H; Ronot M; Podgórska J; Rosiak G; Song JS; Bashir MR
    Radiology; 2023 Dec; 309(3):e231656. PubMed ID: 38112549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging.
    Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K
    Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
    Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
    Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
    Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
    J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
    Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
    Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
    Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
    Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
    Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
    Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
    Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.